| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1126887771 |
| P356 | DOI | 10.1016/J.DIABRES.2020.108162 |
| P932 | PMC publication ID | 7179491 |
| P698 | PubMed publication ID | 32335097 |
| P2093 | author name string | Dario Pitocco | |
| Alfredo Pontecorvi | |||
| Linda Tartaglione | |||
| Salvatore Caputo | |||
| Luca Viti | |||
| Mauro Di Leo | |||
| P2860 | cites work | Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention | Q89855853 |
| Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses | Q89866691 | ||
| COVID-19 and diabetes: Can DPP4 inhibition play a role? | Q90731679 | ||
| Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 | Q90754574 | ||
| Middle East Respiratory Syndrome-Coronavirus Infection into Established hDPP4-Transgenic Mice Accelerates Lung Damage Via Activation of the Pro-Inflammatory Response and Pulmonary Fibrosis | Q91987064 | ||
| Severe leucopenia associated with Sitagliptin use | Q82236755 | ||
| Structure analysis of the receptor binding of 2019-nCoV | Q87461487 | ||
| Rhinorrhea, cough and fatigue in patients taking sitagliptin | Q33878740 | ||
| A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide | Q34661843 | ||
| Role of CD26/dipeptidyl peptidase IV in human T cell activation and function | Q36992436 | ||
| Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? | Q37715226 | ||
| CD26: a surface protease involved in T-cell activation | Q39005893 | ||
| Sitagliptin intolerance | Q43017400 | ||
| Sitagliptin-associated angioedema | Q43229455 | ||
| Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus. | Q51733912 | ||
| Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4. | Q55450249 | ||
| Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes | Q57477167 | ||
| Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease | Q59351890 | ||
| Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness | Q72212768 | ||
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| P304 | page(s) | 108162 | |
| P577 | publication date | 2020-04-23 | |
| P1433 | published in | Diabetes Research and Clinical Practice | Q15750054 |
| P1476 | title | SARS-CoV-2 and DPP4 inhibition: is it time to pray for Janus Bifrons? |
Search more.